Cervical Cancer Screening with Self-HPV Swab

Current Regulatory Status

• The American Cancer Society explicitly states that self-sampling is not included in their 2020 guideline recommendations and should only be used within research protocols until regulatory approval is obtained 1
• All current U.S. guidelines recommend clinician-collected samples for HPV testing, whether used alone or with cytology 2, 3

Evidence Supporting Future Use

• Self-sampling has comparable sensitivity to clinician-collected samples for detecting high-grade cervical lesions when using molecular HPV testing 1
• The method is particularly valuable for reaching never-screened or under-screened populations who face barriers to clinic-based screening 1

Critical Limitations and Caveats

• Self-sampling is NOT appropriate for cytology-based screening because cytology requires adequate cellular material with preserved morphologic features that are difficult to obtain through self-collection 1
• Molecular HPV testing is essential if self-sampling is to be used, as these assays are less affected by specimen adequacy issues 1

Prerequisites Before Clinical Implementation

• Strict adherence to validated protocols for sample collection, storage, and transport is necessary 1
• Unimpeded access to appropriate follow-up, including colposcopy and treatment for positive results, is required 1
• Clear identification of target populations most likely to benefit, particularly those who are under-screened or never-screened, is needed 1
• Use of FDA-approved HPV tests validated for self-collected specimens is necessary 1

Populations That May Benefit Most (Once Approved)

• Women who have never been screened or are significantly overdue for screening may benefit from self-sampling 1
• Women aged 30-65 years, the age group for whom HPV testing is recommended, may benefit from self-sampling 3

What NOT to Do

• Do not use self-sampling for women under age 30, as HPV testing is not recommended in this age group due to high rates of transient infections 4
• Do not use self-sampling for cytology testing due to inadequate specimen quality 1
• Do not implement self-sampling without ensuring robust follow-up systems for abnormal results 1
• Do not use self-sampling in high-risk populations who require more intensive surveillance 3, 4